Eton Pharmaceuticals's three largest insider shareholders as of June 06, 2026 are Sean Brynjelsen (President Ceo, 2.89Mn shares), Management Inc. Opaleye (TenPercentOwner, 2.85Mn shares), David Krempa (Chief Business Officer, 630.24K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Norbert G Riedel | - | 67,155 | 0 | 22 Apr, 2026 |
| Management Inc. Opaleye | - | 0 | 2,855,000 | 12 Jun, 2025 |
| Sean Brynjelsen | President Ceo | 2,889,266 | 0 | 14 Jan, 2026 |
| William Wilson Troutman | Cfo, Treasurer Secretary | 23,027 | 0 | 20 Aug, 2021 |
| James R. Gruber | Chief Financial Officer | 213,420 | 0 | 14 Jan, 2026 |
| David Krempa | Chief Business Officer | 630,238 | 0 | 14 Jan, 2026 |
| Ipek Erdogan-Trinkaus | Chief Commercial Officer | 2,403 | 0 | 12 Dec, 2025 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 21 Apr, 2026 | Norbert G Riedel | Common Stock | A | 12,500 | $7.31 | 47,500 | D | M |
| 21 Apr, 2026 | Norbert G Riedel | Common Stock | A | 12,500 | $7.31 | 47,500 | D | M |
| 21 Apr, 2026 | Norbert G Riedel | Common Stock | A | 19,655 | $8.61 | 67,155 | D | M |
| 21 Apr, 2026 | Norbert G Riedel | Common Stock | A | 19,655 | $8.61 | 67,155 | D | M |
| 21 Apr, 2026 | Norbert G Riedel | Employee Stock Option (Right to Buy) | D | 12,500 | $0.00 | 0 | D | M |
| 21 Apr, 2026 | Norbert G Riedel | Employee Stock Option (Right to Buy) | D | 12,500 | $0.00 | 0 | D | M |
| 21 Apr, 2026 | Norbert G Riedel | Employee Stock Option (Right to Buy) | D | 19,655 | $0.00 | 0 | D | M |
| 21 Apr, 2026 | Norbert G Riedel | Employee Stock Option (Right to Buy) | D | 19,655 | $0.00 | 0 | D | M |
| 03 Feb, 2026 | Norbert G Riedel | Common Stock | A | 30,000 | $4.42 | 35,000 | D | X |
| 03 Feb, 2026 | Norbert G Riedel | Common Stock | A | 30,000 | $4.42 | 35,000 | D | X |
| 03 Feb, 2026 | Norbert G Riedel | Common Stock | A | 30,000 | $4.42 | 35,000 | D | X |
| 03 Feb, 2026 | Norbert G Riedel | Employee Stock Option (Right to Buy) | D | 30,000 | $0.00 | 0 | D | X |
| 03 Feb, 2026 | Norbert G Riedel | Employee Stock Option (Right to Buy) | D | 30,000 | $0.00 | 0 | D | X |
| 03 Feb, 2026 | Norbert G Riedel | Employee Stock Option (Right to Buy) | D | 30,000 | $0.00 | 0 | D | X |
| 14 Jan, 2026 | David Krempa | Common Stock | D | 1,942 | $15.62 | 630,238 | D | F |
| 12 Jan, 2026 | Charles J Casamento | Employee Stock Option (Right to Buy) | A | 12,196 | $0.00 | 295,171 | D | A |
| 14 Jan, 2026 | David Krempa | Common Stock | D | 1,942 | $15.62 | 630,238 | D | F |
| 01 Jan, 2026 | Sean Brynjelsen | Common Stock | D | 5,015 | $15.39 | 2,889,266 | D | F |
| 12 Jan, 2026 | Jennifer Mckie Adams | Employee Stock Option (Right to Buy) | A | 12,196 | $0.00 | 170,329 | D | A |
| 14 Jan, 2026 | James R. Gruber | Common Stock | D | 2,293 | $15.47 | 213,420 | D | F |